These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 8993504)
1. Induction of apoptosis by camptothecin and topotecan. Traganos F; Seiter K; Feldman E; Halicka HD; Darzynkiewicz Z Ann N Y Acad Sci; 1996 Dec; 803():101-10. PubMed ID: 8993504 [No Abstract] [Full Text] [Related]
2. Induction of apoptosis by topotecan: implications for the treatment of leukemia. Seiter K Semin Hematol; 1998 Jul; 35(3 Suppl 4):22-5. PubMed ID: 9779878 [TBL] [Abstract][Full Text] [Related]
3. Differential effect of camptothecin treatment on topoisomerase II alpha expression in ML-1 and HL-60 leukemia cell lines. Nair J; Traganos F; Tse-Dinh YC Anticancer Res; 2000; 20(6B):4183-8. PubMed ID: 11205246 [TBL] [Abstract][Full Text] [Related]
4. The cell cycle effects of camptothecin. Darzynkiewicz Z; Bruno S; Del Bino G; Traganos F Ann N Y Acad Sci; 1996 Dec; 803():93-100. PubMed ID: 8993503 [No Abstract] [Full Text] [Related]
8. Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors. McDonald AC; Brown R Br J Cancer; 1998 Sep; 78(6):745-51. PubMed ID: 9743293 [TBL] [Abstract][Full Text] [Related]
9. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity. Morris EJ; Geller HM J Cell Biol; 1996 Aug; 134(3):757-70. PubMed ID: 8707853 [TBL] [Abstract][Full Text] [Related]
10. Pre-clinical evaluation of SN-38 and novel camptothecin analogs against human chronic B-cell lymphocytic leukemia lymphocytes. Cohen DP; Adams DJ; Flowers JL; Wall ME; Wani MC; Manikumar G; Colvin OM; Silber R Leuk Res; 1999 Nov; 23(11):1061-70. PubMed ID: 10576512 [TBL] [Abstract][Full Text] [Related]
11. Caffeine prevents apoptosis and cell cycle effects induced by camptothecin or topotecan in HL-60 cells. Traganos F; Kapuscinski J; Gong J; Ardelt B; Darzynkiewicz RJ; Darzynkiewicz Z Cancer Res; 1993 Oct; 53(19):4613-8. PubMed ID: 8402636 [TBL] [Abstract][Full Text] [Related]
12. Anti-proliferative and apoptosis-inducing effects of camptothecin-20(s)-O-(2-pyrazolyl-1)acetic ester in human breast tumor MCF-7 cells. Chu C; Xu J; Cheng D; Li X; Tong S; Yan J; Li Q Molecules; 2014 Apr; 19(4):4941-55. PubMed ID: 24747650 [TBL] [Abstract][Full Text] [Related]
13. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it? Jung LL; Zamboni WC Drug Resist Updat; 2001 Aug; 4(4):273-88. PubMed ID: 11998845 [TBL] [Abstract][Full Text] [Related]
14. Camptothecin causes cell cycle perturbations within T-lymphoblastoid cells followed by dose dependent induction of apoptosis. Johnson N; Ng TT; Parkin JM Leuk Res; 1997 Oct; 21(10):961-72. PubMed ID: 9403007 [TBL] [Abstract][Full Text] [Related]
15. Topoisomerase I inhibitors: topotecan and irinotecan. Jones SF; Burris HA Cancer Pract; 1996; 4(1):51-3. PubMed ID: 8788772 [No Abstract] [Full Text] [Related]
16. Topoisomerase I inhibition by the camptothecin analog Gl147211C. From the laboratory to the clinic. Besterman JM Ann N Y Acad Sci; 1996 Dec; 803():202-9. PubMed ID: 8993513 [TBL] [Abstract][Full Text] [Related]
17. [The effect of hydroxycamptothecin and topotecan to SKOV3 and CAOV3 in vitro]. Sun Z; Shen K; Xu X Zhonghua Fu Chan Ke Za Zhi; 1999 Sep; 34(9):547-50. PubMed ID: 11360641 [TBL] [Abstract][Full Text] [Related]